Position Statements

POSITION STATEMENT ON FREESTYLE LIBRE FOR GLUCOSE MONITORING

The following guidance represent the consensus of ABCD ,Type 1 Diabetes Clinical Collaborative-UK, ACDC and the National Children and Young People’s Diabetes Network for FreeStyle Libre for glucose monitoring .

The guidance has been produced for diabetes teams to use in their discussions with purchasing organisations to ensure the benefit of the technology is realised in as many people as possible, consistently across the NHS. The guidance  should be used as an adjunct to Diabetes UK’s Consensus statement on Flash Glucose Monitoring, Abbott’s Formulary Pack and NICE MIB 110

Guidance to help a formulary case :  InfoFormularyFreestyleLibre

The  Regional Medicines Optimisation Committee (RMOC) position statement on the NHS prescribing of Freestyle Libre® Flash Glucose Monitoring System is now endorsed by the Northern Treatment Advisory Group for patients in the North East and Cumbria, by Greater Manchester Medicines Group for patients in Greater Manchester, by the Area Prescribing Committee in Brighton and by Health Technology Wales.

FreeStyle-Libre-New-Drug-final-recommendation-FNL

Freestyle libre NTAG position statement Nov 2017 – final

Freestyle Libre Flash Monitoring System – CCG position Nov17 BHandHWLH

HTW-Statement-FreeStyle-Libre-glucose-monitoring-v1.1

Please note that there is a criteria to commit to ongoing regular follow-up and monitoring and that audit data from all patients should be submitted. Freestyle Libre data from children’s diabetes units can be included in the ABCD National Libre Audit as part of a collaboration between ABCD and ACDC

https://abcd.care/launch-abcd-nationwide-freestyle-libre-audit